VX-770 的 2A 期、随机、双盲、安慰剂对照研究以进行评估-猫眼课题宝

VX-770 的 2A 期、随机、双盲、安慰剂对照研究以进行评估

批准号：

7951737

负责人：

JORDAN M DUNITZ

金额：

$0.18万

依托单位：

UNIVERSITY OF MINNESOTA

依托单位国家：

美国

项目类别：

财政年份：

2008

资助国家：

美国

项目状态：

已结题

起止时间：

2008-12-01 至 2009-11-30

来源：

https://reporter.nih.gov/project-details/7951737

关键词：

Clinical Research Computer Retrieval of Information on Scientific Projects Database Cystic Fibrosis Double-Blind Method Funding Grant Institution Phase Randomized Research Research Personnel Resources Source United States National Institutes of Health VX-770 cystic fibrosis patients novel placebo controlled study therapy development

中文摘要

翻译

这个子项目是众多研究子项目之一

英文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study hypothesis is that VX770, a novel compound in development for the treatment of cystic fibrosis (CF), is safe and well tolerated by CF patients.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文